BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34038071)

  • 1. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
    Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
    ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
    Peng ZH; Kopeček J
    J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
    Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H
    ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
    Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
    J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
    Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
    Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
    Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
    Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles.
    Huang J; Lai W; Wang Q; Tang Q; Hu C; Zhou M; Wang F; Xie D; Zhang Q; Liu W; Zhang Z; Zhang R
    Int J Nanomedicine; 2021; 16():7497-7515. PubMed ID: 34803378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy.
    Chen J; Yang Q; Liu M; Lin M; Wang T; Zhang Z; Zhong X; Guo N; Lu Y; Xu J; Wang C; Han M; Wei Q
    Int J Nanomedicine; 2019; 14():8161-8177. PubMed ID: 31632025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
    Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
    ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iRGD mediated pH-responsive mesoporous silica enhances drug accumulation in tumors.
    Wang X; Zhao Y; Yan M; Liang X; Zhao N; Lu T
    Eur J Pharm Sci; 2024 Apr; 195():106725. PubMed ID: 38346565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
    Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
    J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milk derived colloid as a novel drug delivery carrier for breast cancer.
    Hayashi M; Silanikove N; Chang X; Ravi R; Pham V; Baia G; Paz K; Brait M; Koch WM; Sidransky D
    Cancer Biol Ther; 2015; 16(8):1184-93. PubMed ID: 26046946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.